Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer
JAMA Network Open · 2023
DOI: 10.1001/jamanetworkopen.2023.26546 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, 2023. Verfasst von Nicolas Sayegh und 11 weiteren Autor:innen. Beteiligte Einrichtung: Huntsman Cancer Institute, University of Utah, Salt Lake City. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 8 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Importance Black patients present with more aggressive disease and experience higher mortality than White patients with prostate cancer. Race and social determinants of health influence prostate cancer-specific mortality and overall survival (OS); however, in a previous trial, Black patients did not have inferior outcomes compared with White patients, possibly because of equitable access to care available in a clinical trial setting.
Objective
To compare differences in survival outcomes of patients with metastatic castration-sensitive prostate cancer (mCSPC) by race in a phase 3 trial with a large proportion of Black patients. Design, Setting, and Participants This secondary analysis of patient-level data of a prospective phase 3 randomized clinical trial included patients with newly diagnosed mCSPC enrolled between March 1, 2013, and July 15, 2017. Analysis was conducted between December 2022 and February 2023.
Interventions
Patients receiving androgen deprivation therapy were randomized (1:1) to receive either orteronel 300 mg orally twice daily (experimental group) or bicalutamide 50 mg orally daily (control group). Main Outcomes and Measures OS, with progression-free survival (PFS) as a secondary end point.
Results
Among 1313 participants, 135 (10%) identified as Black and 1077 (82%) as White, with an equal racial distribution between groups. Black patients were younger (median [IQR] age, 65.8 [60-70] vs 68.4 [62.5-74.1] years; P = .001) and had a higher median (IQR) baseline prostate-specific antigen response rate than White patients (54.7 [19.8-222.0] vs 26.7 [9.2-96.0] ng/mL; P < .001). At a median follow-up of 4.9 years, Black and White patients had similar median PFS (2.3 years; 95% CI, 1.8-1.4 years vs 2.9 years; 95% CI, 2.5-3.3 years; P = .71) and OS (5.5 years; 95% CI, 4.8-NR vs 6.3 years; 95% CI, 5.7-NR; P = .65). The multivariable analysis confirmed similar PFS and OS after adjusting for known prognostic factors. No interaction between race and treatment was observed. Conclusions and Relevance In this secondary analysis of a randomized clinical trial studying androgen deprivation therapy with first- or second-generation androgen receptor pathway inhibitors, both Black and White patients demonstrated similar OS and PFS. Equitable access to care may reduce historical differences in outcomes between Black and White patients with advanced prostate cancer. Trial Registration ClinicalTrials.gov Identifier: NCT01809691
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Huntsman Cancer Institute, University of Utah, Salt Lake City.
- Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio.
- Southwest Oncology Group Statistics and Data Management Center, Seattle, Washington.
- Northwestern University, Feinberg School of Medicine, Chicago, Illinois.
- University of Southern California Norris Comprehensive Cancer Center, Los Angeles.
- University of California Davis Comprehensive Cancer Center, Sacramento.
Förderung
- NCI NIH HHS
Zitieren
APA
Sayegh, N., Swami, U., Jo, Y., Gebrael, G., Haaland, B., Gupta, S., Plets, M., Hussain, M. H. A., Quinn, D. I., Lara, P. N., Thompson, I. M., & Agarwal, N. (2023). Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.26546
Vancouver
Sayegh N, Swami U, Jo Y, Gebrael G, Haaland B, Gupta S, et al. Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer. JAMA Network Open. 2023. doi:10.1001/jamanetworkopen.2023.26546
BibTeX
@article{Sayegh2023,
author = {Sayegh, Nicolas and Swami, Umang and Jo, Yeonjung and Gebrael, Georges and Haaland, Benjamin and Gupta, Shilpa and Plets, Melissa and Hussain, Maha H A and Quinn, David I and Lara, Primo N and Thompson, Ian M and Agarwal, Neeraj},
title = {Race and Treatment Outcomes in Patients With Metastatic Castration-Sensitive Prostate Cancer},
journal = {JAMA Network Open},
year = {2023},
doi = {10.1001/jamanetworkopen.2023.26546}
}
EUVIMED